ADMA vs KNSA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.
KNSA exhibits strong deterministic health with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.02), yet it faces a severe valuation disconnect. The current price of $47.08 trades at a massive premium to its Graham Number ($11.20) and Intrinsic Value ($5.25), suggesting the market is pricing in aggressive future growth. While revenue growth is impressive at 65% YoY, the company has missed earnings estimates in 4 consecutive quarters with an average surprise of -35.29%. This fundamental instability, coupled with heavy C-suite insider selling and a bearish technical trend, offsets the strong financial health.
Compare Another Pair
Related Comparisons
ADMA vs KNSA: Head-to-Head Comparison
This page compares ADMA Biologics, Inc. (ADMA) and Kiniksa Pharmaceuticals International, plc (KNSA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.